阳性MCM6-c-Myc反循环调解了膀癌的进展和对西斯普拉丁的耐药性
Jirong Wang1, Xiaoran Li2, Liwei Zhao2
1Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China; Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China; Cuiying Biomedical Research Center, Lanzhou University Second Hospital.
International journal of biological macromolecules
|January 13, 2025
概括
迷你染色体维护6 (MCM6) 通过增强DNA损伤修复,驱动膀癌 (BLCA) 的化学抵抗. 向MCM6可能会克服BLCA患者的西斯普拉丁耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 化疗对于膀癌 (BLCA) 治疗至关重要,但化疗抵抗限制了其有效性.
- 了解BLCA化学抵抗的分子基础对于改善患者存活率和治疗结果至关重要.
研究的目的:
- 为了确定驱动膀癌中化学抵抗的分子机制.
- 调查MCM6在BLCA扩散,入侵和西斯抗药性中的作用.
主要方法:
- 在BLCA中确定了MCM6作为瘤基因.
- 在BLCA组织中分析的MCM6表达与化疗反应相关.
- 在BLCA细胞中进行了MCM6敲除的体外和体内研究.
- 研究了MCM6,c-Myc和DNA损伤修复 (DDR) 之间的机制联系.
主要成果:
- 鉴定出MCM6是一种促进BLCA扩散和入侵的瘤基因,并与西斯普拉丁耐药性有关.
- 在化学疗法反应不佳的BLCA组织中,MCM6的表达被上调.
- 在BLCA细胞中,MCM6的淘汰会增加青的敏感性,无论是体外还是体外.
- 通过促进DNA损伤的修复,MCM6增强了对西斯的抗性;MCM6的敲除降低了核c-Myc水平,增加了DNA损伤.
- c-Myc直接与MCM6促进体结合,调节其转录.
结论:
- MCM6是膀癌中西斯替林耐药性的关键驱动因素.
- 准MCM6介导的DNA损伤修复是克服BLCA化学抵抗的潜在策略.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


